Whereas EZH inhibits NFE2L2 expression and decreases NSCLC growth in vivo and in vitro [125], hypermethylation of KEAP1 promoter inhibits its expression and results in increased NRF2 levels [164]. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.